Please login to the form below

Not currently logged in
Email:
Password:

galcanezumab

This page shows the latest galcanezumab news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Novartis migraine treatment Aimovig

NICE rejects Novartis migraine treatment Aimovig

Novartis has a number of competitors in the CGRP class hot on its heels: Lilly's Emgality (galcanezumab) gained EU approval in November, and is now entering the NICE appraisal process.

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics